PDCD1, CTLA-4 and p53 gene polymorphism and susceptibility to gestational trophoblastic diseases

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 54, Issue 1, 2009, Pages 25-31

  Dehaghani, Alamtaj Samsami ^a   Kashef, Mohammad Amin ^a   Ghaemenia, Mehdi ^a   Sarraf, Zahra ^a   Khaghanzadeh, Narges ^a   Fattahi, Mohammad Javad ^a   Ghaderi, Abbas ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CTLA 4; Gestational trophoblastic neoplasms; p53; Polymorphism; Programmed death 1 (PD 1)

Indexed keywords

ARGININE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; PROLINE; PROTEIN P53; PROTEIN PDCD1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNOREGULATION; IRAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TROPHOBLASTIC TUMOR; TUMOR GROWTH;

ADULT; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CASE-CONTROL STUDIES; CHORIOCARCINOMA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDATIDIFORM MOLE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 60949111746     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Genest DR, Berkowitz RS, Fisher RA, et al: Gestational trophoblastic disease. In World Health Organization Classification of Tumors, Pathology and Genetics: Tumors of the Breast and Female Genital Organs. Edited by FA Tavassoli, P Devilee. Lyon, IARC Press, 2003, pp 250-254
2. Ng TY, Wong LC: Diagnosis and management of gestational trophoblastic neoplasia. Best Pract Res Clin Obstet Gynaecol 2003;17:893-903
3. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol 2005;23:515-548
4. Nishimura H, Okazaki T, Tanaka Y, et al: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;12:319-322
5. Petroff MG, Chen L, Phillips TA, et al: B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol Reprod 2003;68:1496-1504
6. Blank C, Mackensen A: Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56:739-745
7. Nomi T, Sho M, Akahori T, et al: Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151-2157
8. Hamanishi J, Mandai M, Iwasaki M, et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;27:3360-3365
9. Prokunina L, Castillejo-Lopez C, Oberg F, et al: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32:666-669
10. Lin SC, Yen JH, Tsai JJ, et al: Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 2004;50:770-775
11. Lee SH, Lee YA, Woo DH, et al: Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther 2006;8:R163
12. Teft WA, Kirchhof MG: A molecular prospective of CTLA-4 function. Annu Rev Immunol 2006;24:65-97
13. Chambers CA, Allison JP: Co-stimulation in T cell responses. Curr Opin Immunol 1997;9:396-404
14. Ghaderi A, Yeganeh F, Kalantari T, et al: Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 2004;86:1-7
15. Samsami Dehaghani A, Doroudchi M, Kalantari T, et al: Heterozygosity in CTLA-4 gene and severe preeclampsia. Int J Gynaecol Obstet 2005;88:19-24
16. Kaufman KA, Bowen JA, Tsai AF, et al: The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod 1999;5:84-87
17. Heikkinen J, Mottonen M, Alanen A, et al: Phenotypic characterization of regulatory T cells in the human decidua. Clin Exp Immunol 2004;136:373-378
18. Miwa N, Hayakawa S, Miyazaki S, et al: IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferongamma increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod 2005;11:865-870
19. Ko LJ, Prives C: p53: Puzzle and paradigm. Genes Dev 1996;10:1054-1072
20. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;7:323-331
21. Cadwell C, Zambetti GP: The effects of wild-type p53 rumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001;277:15-30
22. Donehower LA: p53 guardian and suppressor of longevity? Exp Gerontol 2005;40:7-9
23. Tada M, Furuuchi K, Kaneda M, et al: Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001;22:515-517
24. Dumont P, Leu JI, Della Pietra AC, et al: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-365
25. Thomas M, Kalita A, Labrecque S, et al: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-1100
26. Yazaki-Sun S, Daher S, de Souza Ishigai MM, et al: Correlation of c-erbB-2 oncogene and p53 tumor suppressor gene with malignant transformation of hydatidiform mole. J Obstet Gynecol Res 2006;32:265-272
27. Halperin R, Peller S, Sandbank J, et al: Expression of the p53 gene and apoptosis in gestational trophoblastic disease. Placenta 2000;21:58-62
28. Cheung ANY, Srivastava G, Chung LP, et al: Expression of the p53 gene in trophoblastic cells in hydatidiform moles and normal hum placentas. J Reprod Med 1994;39:223-227
29. Petignat P, Laurini R, Goffin F, et al: Expression of matrix metalloproteinase-2 and mutant p53 is increased in hydatidiform mole as compared with normal placenta. Int J Gynecol Cancer 2006;16:1679-1684
30. Yaginuma Y, Yamashita T, Takuma N, et al: Analysis of the p53 gene in human choriocarcinoma cell lines. Br J Cancer 1995;71:9-12
31. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215
32. Donner H, Rau H, Walfish PG, et al: CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 1997;82:143-146
33. Bourn D, Carter SA, Mason S, et al: Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet 1994;3:813-816
34. Kong EK, Prokunina-Olsson L, Wong WH, et al: A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005;52:1058-1062
35. Wang X, Lin Q, Ma Z, et al: Association of the A/G polymorphism at position 49 in exon 1 of CTLA-4 with the susceptibility to unexplained recurrent spontaneous abortion in the Chinese population. Am J Reprod Immunol 2005;53:100-105
36. Monne M, Piras G, Palmas A, et al: Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Am J Hematol 2004;76:14-18
37. Van Heemst D, Mooijaart SP, Beekman M, et al: Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 2005;40:11-15